Mycosis Clinical Trials

48 recruitingLast updated: July 25, 2026

There are 48 actively recruiting mycosis clinical trials across 17 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Duarte, California, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Mycosis Trials at a Glance

48 actively recruiting trials for mycosis are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Houston, Duarte, and New York. Lead sponsors running mycosis studies include M.D. Anderson Cancer Center, City of Hope Medical Center, and Institute of Hematology & Blood Diseases Hospital, China.

Treatments under study

About Mycosis Clinical Trials

Looking for clinical trials for Mycosis? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mycosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mycosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 48 trials

Recruiting
Phase 1Phase 2

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Phase 1

Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections

AspergillosMucormyeDimorphic+3 more
National Institutes of Health Clinical Center (CC)100 enrolled1 locationNCT07704333
Recruiting

Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

Coccidioidomycosis
National Institute of Allergy and Infectious Diseases (NIAID)400 enrolled1 locationNCT02190266
Recruiting

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Mycosis FungoidesLymphomatoid Papulosis
M.D. Anderson Cancer Center100 enrolled1 locationNCT06207812
Recruiting

Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

Mucormycosis
M.D. Anderson Cancer Center300 enrolled1 locationNCT06878144
Recruiting
Phase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Breast CancerLiver CancerColorectal, Cancer+19 more
University of California, Irvine75 enrolled1 locationNCT06580002
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 2

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Mycosis FungoidesSezary Syndrome
Stanford University30 enrolled1 locationNCT04256018
Recruiting
Not Applicable

Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.

Facial asymmetryOral Squamous Cell CarcinomaMucormycosis+3 more
Latakia University30 enrolled1 locationNCT07654647
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting

Biomarkers for Invasive Mucormycosis

Mucorales InfectionMucormycosis
University Hospital, Lille100 enrolled1 locationNCT05406037
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 2

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
University of Michigan Rogel Cancer Center23 enrolled1 locationNCT05956041
Recruiting
Early Phase 1

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Mycosis Fungoides
Northwestern University25 enrolled1 locationNCT05838599
Recruiting
Phase 2

Photopheresis in Early-stage Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting
Phase 1

Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis

Onychomycosis
Zagazig University36 enrolled1 locationNCT06485505
Recruiting
Phase 2

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Mycosis FungoidesLocalized Skin Lesion
M.D. Anderson Cancer Center50 enrolled1 locationNCT03398161
Recruiting

Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota

DysbiosisHPVMycosis+5 more
Centre National de la Recherche Scientifique, France300 enrolled1 locationNCT07199998
Recruiting
Phase 1

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
University of Alabama at Birmingham10 enrolled1 locationNCT05414500